US2009246129A1PendingUtilityA1

Compositions and methods for the diagnosis and treatment of tumor

70
Assignee: CAIMS BELINDAPriority: Jun 20, 2001Filed: Feb 9, 2009Published: Oct 1, 2009
Est. expiryJun 20, 2021(expired)· nominal 20-yr term from priority
Inventors:Belinda CaimsRuihuan ChenGretchen FrantzKenneth HillanHartmut KoeppenHeidi S. PhillpsPaul PolakisSusan D. SpencerVictoria SmithP. WilliamsThomas WuZemin Zhang
A61P 35/00C07K 16/18C07K 16/3023A61P 31/00C07K 16/40A61K 47/6809A61K 47/6843A61K 47/6851A61K 2039/505C07K 2317/73C07K 16/30G01N 33/57557A61K 47/68033
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Claims

exact text as granted — not AI-modified
1 - 105 . (canceled) 
     
     
         106 . A method of inhibiting the growth of a cell that expresses a protein comprising amino acids 30-553 of the amino acid sequence shown in  FIG. 85  (SEQ ID NO:85), said method comprising contacting said cell with an antibody that binds to said protein, the binding of said antibody to said protein thereby causing an inhibition of growth of said cell. The method of  claim 106 , wherein said antibody is a monoclonal antibody. 
     
     
         107 . The method of  claim 106 , wherein said antibody is an antibody fragment. 
     
     
         108 . The method of  claim 106 , wherein said antibody is a chimeric or a humanized antibody. 
     
     
         109 . The method of  claim 106 , wherein said antibody is conjugated to a growth inhibitory agent. 
     
     
         110 . The method of  claim 106 , wherein said antibody is conjugated to a cytotoxic agent. 
     
     
         111 . The method of  claim 110 , wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes. 
     
     
         112 . The method of  claim 110 , wherein the cytotoxic agent is a toxin. 
     
     
         113 . The method of  claim 112 , wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin. 
     
     
         114 . The method of  claim 112 , wherein the toxin is a maytansinoid. 
     
     
         115 . The method of  claim 106 , wherein said antibody is produced in bacteria. 
     
     
         116 . The method of  claim 106 , wherein said antibody is produced in CHO cells. 
     
     
         117 . The method of  claim 106 , wherein said cell is a cancer cell. 
     
     
         118 . The method of  claim 117 , wherein said cancer cell is a colon cancer cell. 
     
     
         119 . The method of  claim 117 , wherein said cancer cell is further exposed to radiation treatment or a chemotherapeutic agent. 
     
     
         120 . The method of  claim 106  which causes the death of said cell. 
     
     
         121 . A method of therapeutically treating a mammal having a cancerous tumor comprising cells that express a protein comprising amino acids 30-553 of the amino acid sequence shown in  FIG. 85  (SEQ ID NO:85), said method comprising administering to said mammal a therapeutically effective amount of an antibody that binds to said protein, thereby effectively treating said mammal. 
     
     
         122 . The method of  claim 121 , wherein said antibody is a monoclonal antibody. 
     
     
         123 . The method of  claim 121 , wherein said antibody is an antibody fragment. 
     
     
         124 . The method of  claim 121 , wherein said antibody is a chimeric or a humanized antibody. 
     
     
         125 . The method of  claim 121 , wherein said antibody is conjugated to a growth inhibitory agent. 
     
     
         126 . The method of  claim 121 , wherein said antibody is conjugated to a cytotoxic agent. 
     
     
         127 . The method of  claim 126 , wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes. 
     
     
         127 . The method of  claim 126 , wherein the cytotoxic agent is a toxin. 
     
     
         128 . The method of  claim 127 , wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin. 
     
     
         129 . The method of  claim 128 , wherein the toxin is a maytansinoid. 
     
     
         130 . The method of  claim 121 , wherein said antibody is produced in bacteria. 
     
     
         131 . The method of  claim 121 , wherein said antibody is produced in CHO cells. 
     
     
         132 . The method of  claim 121 , wherein said tumor is further exposed to radiation treatment or a chemotherapeutic agent. 
     
     
         133 . The method of  claim 121 , wherein said tumor is a colon tumor.

Join the waitlist — get patent alerts

Track US2009246129A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.